In a study on advanced endometrial cancer, patients were administered either 100 mg/m2 (22 patients) or 120 mg/m2 (42 patients) of Rina-S. The confirmed overall response rate was 50% in the 100 mg/m2 group, with two complete responses. For the 120 mg/m2 group, the confirmed response rate was 47.1%, indicating anti-tumor activity. The median duration of response had not been reached at the time of analysis, with a median follow-up of 7.7 months in the 100 mg/m2 group and 9.8 months in the 120 mg/m2 group. The median ages of patients were 67 and 69.5 years in the respective cohorts, with a median of three prior treatments received.
Read more from curetoday.com
